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Summary: The clinical and biochemical outcome of a liver transplantation in a seven-year-old boy with acute
porphyria due to aminolaevulinate dehydratase deficiency is described. Before transplantation standard liver
function tests were normal and the rationale for transplantation was that the new liver would reduce the
metabolic disturbance and thus avert the porphyric symptoms. During the year after the transplantation, the
functioning of the new liver has been excellent. Basal excretion of porphyrin and porphyrin precursors has
remained unchanged but, with the new liver transplant the patient has been able to withstand several
porphyrinogenic challenges without increasing the excretion. Episodes of neurological and respiratory crises
may have been due to persistent porphyric vulnerability. Alternatively, two early attacks may have been
caused by neurotoxic effects of cyclosporin in combination with the existing damage to nervous tissue.
Introduction T . , 1· A * 1 ·, . j /- · i -In aminolaevulinate dehydratase deficiency porphyria
The acute hepatic porphyrias comprise a group of symptoms develop only in individuals who are homo-
inborn errors of porphyrin metabolism characterized zygous or double-heterozygous for the condition in
by the development, in some individuals, of a severe question (1 — 5).
neuropsychiatric syndrome: the acute porphyric at- „~ Γ Γ ~ , - . , ^u r ,ι £ι/ Λ ι · - ι ι - j · The four forms of acute porphyria, share the featuretack. The underlying mutations are localized in genes ~ c . , r . <, .· ·.« «. ^.,, r , - r ,™ of 5-aminolaevulmate overproduction with two otherresponsible for the production of different enzymes . - r « . . . . . « , , . , .. . , Γ · j · · j j metabolic conditions, tyrosmaemia and lead intoxi-active in haem synthesis and give rise to a reduced .. - . - , ... . .. 1 - 1. . „ , ' , , . „ cation, which present with similar neurological symp-activity of the affected enzyme and accumulation of „,, _ . , ,. f .^ ^ \_— / - toms. Thus, 5-aminolaevulmate or one of its metab-metabohtes. Four types of acute porphyria are rec- .. , 1 - 1 , 1 . ^ ^. Λ ^ t , _ . . . , - ohtes, may play a role in the development of theognized. Thus heterozygous deficiencies in porphob- A . , 1 0 . ι Α *... , , . t , typical neuropathy. Some experimental support tormnogen deammase, coproporphynnogen oxidase and -: - - . , . 1 A . , ,, ΛΓ.. ^,
t . .j - t. ,- - , this hypothesis has been obtained (6 — 10). The ac-protoporphynnogen oxidase produce the clinical con- / . r _ . , r . , . ' ... . r . . , · , ι· cumulation of 5-aminolaevulmate is obviously due toditions of acute intermittent porphyria, hereditary . . J , ,- , . , . . . the inability of a decreased aminolaevulinate dehy-coproporphyna and variegate porphyria, respectively. Λ . . . ^ . - Λ f , - .dratase activity to meet the need for haem synthesis.
This situation may be precipitated by a variety of
* Now: Department of Pediatrics, University of Gothenburg, exogenous and endogenous agents which act by re-
Eastern Hospital, Gothenburg, Sweden. ducing the cellular free haem pool, the size of which
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regulates the activity of the haem pathway. Several
drugs and biocides, as well as alcohol, stress, fasting
and infection, have been implicated in this context.
The mechanism seems to depend on a consumption
of haem for production of cytochrome P450 or an
induction of the haem degrading oxygenase enzyme,
both of which are considered to be mainly or wholly
confined to the liver (11).
The critical role assigned to the liver in acute por-
phyria suggests that exchange of the porphyric liver
by a normal organ should eliminate the basis for the
neurological crises. Thus, in the last few years a num-
ber of patients with liver-based metabolic diseases
have been treated by liver transplantation, although
standard liver function tests have been normal. In
these cases, the aim of the procedure has been to cure
the patient's disease by correction of the metabolic
deficiency. The first such liver transplantation was
performed in a patient with familial hypercholester-
olaemia (12). More recently, several patients with
primary hyperoxaluria have undergone such "meta-
bolic" liver transplantation. Liver transplantations
have also been performed in a few patients with
erythropoietic protoporphyria due to imminent liver
failure (13 — 15). Liver exchange has, however, not
been attempted in acute porphyria. The relentless
clinical deterioration in some porphyric patients and
the risk of fatal exacerbations does seem to justify
liver exchange as a therapeutic option. In the present
communication the clinical and biochemical outcomes
of liver transplantation in a boy with acute porphyria
due to aminolaevulinate dehydratase deficiency are
described.
Materials and Methods
The methods used to analyse aminolaevulinic acid, porphobi-
linogen, porphyrins and porphyrin isomers in urine and faeces,
and porphyrin, porphobilinogen deaminase activity and ami-
nolaevulinate dehydratase activity in erythrocytes were de-
scribed in a previous communication (4). Blood cyclosporin
concentration was determined by radioimmunological assay,
using a monoclonal specific antibody (Sandoz, Basel, Switzer-
land).
Patient
The clinical course and the diagnosis of aminolaevulinate de-
hydratase deficiency porphyria in our patient were described in
a previous report (4). The diagnosis was based on the findings
of an erythrocyte aminolaevulinate dehydratase activity of less
than 5 percent of normal in the patient and activities between
26 and 51 percent of normal in the parents, in both grandfathers
and in a sibling. The patient excreted large amounts of 5-
aminolaevulinate and coproporphyrin in the urine. Immuno-
chemical data indicated that the enzyme deficiency in the child
was associated with the production of a catalytically abnormal
enzyme protein (16). The genetic defects in the patient were
identified and the condition was found to be connected with
two different mutations in the aminolaevulinate dehydratase
gene, a paternal 823 G to A transition giving rise to methionine
for valine 273 and a maternal 397 G to A transition, resulting
in the substitution of arginine for glycine 133 at the carboxyl
end of the zinc binding site of the enzyme (17).
Symptoms of acute porphyria were present even from birth.
Severe muscular hypotonia and shallow respiration were ob-
served, and the patient needed ventilatory support for five
weeks. EMG revealed an absence of normal motor responses.
After two months the child was discharged, clinically improved
but without a firm diagnosis. At one year of age some hypotonia
persisted but the child could sit steadily, roll around and had
a good pincette grip. Weight gain was satisfactory, but feeding
problems were reported. At about two years of age the child's
conditon started to deteriorate. He showed signs of irritability,
refused oral intake and developed progressive muscular weak-
ness of both legs which seemed to hurt on touching. Ventilatory
support again became necessary. At that time the diagnosis of
aminolaevulinate dehydratase deficiency porphyria was estab-
lished. During the following four and a half years several
porphyric crises occurred with muscular hypotonia, respiratory
distress, anorexia and painful paresthesia. Attemps to treat the
crises by conventional means were generally unsuccessful. Con-
tinuous total parenteral nutrition had to be instituted because
of persistent anorexia and vomiting on attempts at oral or
enteral feeding. Pneumonia and septicaemia occurred fre-
quently. Progressive muscular atrophy was seen and there was
permanent partial phrenic paralysis with impaired respiratory
movements and more or less constant lower pulmonary lobe
atelectasis. Serum bilirubin, albumin and aminotransferase val-
ues were normal and the patient had no symptoms of liver
insufficiency. With the aim of reducing the metabolic disturb-
ance and possibly stopping the progression of the disease, a
hepatic transplantation was decided upon.
Transplantation and Subsequent Clinical Course
The liver transplantation was performed at Huddinge Hospital
in Stockholm in December, 1989, when the patient was six years
and eight months old.
No technical difficulties or complications were encountered
during the anaesthesia or the operation. The macroscopic ap-
pearance of the patient's own liver was normal although the
left lobe was atrophic. Microscopic examination of the specimen
revealed a normal liver, except for mild portal fibrosis. There
were also some small areas with degenerated or necrotic he-
patocytes. A perfectly size-matched liver from an ABO-blood
group identical donor was used.
Because of 950 ml blood loss, 600 ml erythrocyte concentrate
was given peroperatively together with plasma and buffer.
In figure 1, the two-month postoperative period is described.
The 24 hour 5-aminolaevulinate excretion as well as the symp-
toms of the patient, the various medications given and signs of
infection are shown in the diagram.
An episode of Pseudomonas bacteriuria was treated with piper-
acillin and tobramycin. Serum aminotransferase activities nor-
malized after an initial mild ischaemic injury. In the second
week, the serum aminotransferases and bilirubin increased but
they returned to normal within some days. The patient was
mobilized and tolerated physiotherapy. Parenteral nutrition was
changed to enteral nutrition via a nasojejunal tube.
On the 25th day after the operation, the child suddenly devel-
oped severe seizures. The breathing became rapid and superfi-
cial, the heart rate rose to 150 — 160 beats per minute, the
central venous pressure was 7.5 mm Hg and the diastolic
systemic blood pressure 115 — 120 mm Hg. The stomach and
intestines were dilated. Liver function was stable, but hypona-
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Fig. 1. Urinary 5-aminolaevulinate 24 hour excretion, clinical status, signs of infection and initiation and termination of
medications during the six-month postoperative period.
Shaded areas in the diagrams represent values above or below the normal. Substances written in white on a black
background are reported to be porphyrinogenic.
traemia, 130 mmol/l, was present (fig. 1). During a 48-hour
period at least three additional epileptiform crises occurred.
Diazepam, clonazepam, thiopental, morphine and propofol
were used for sedation. Pulmonary infiltrates, probably sec-
ondary to aspiration, were treated with benzylpenicillin and
netilmicin. Rising serum titres against Candida antigen
prompted medication with amphotericin. The patient slowly
improved. After 25 days on a ventilator he was extubated but
he still had poor respiratory function, attacks of bradycardia,
periods of increased blood pressure and, on some occasions,
hyponatraemia. Mycostatin, netilmicin, dicloxacillin and clox-
acillin were used as therapy for pneumonia. After approxi-
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mately six weeks, a grade II graft rejection was diagnosed by
biopsy and was successfully treated with methylprednisolone.
Scintigraphy and liver biopsy 10 weeks after the transplantation
showed a homogeneous uptake and no histopathological
changes.
The patient was transferred to the University Hospital Lund,
in March 1990. Eleven weeks after the operation his neuro-
muscular function deteriorated. Paralysis became total and
included his respiration. He again needed ventilatory support.
The course was complicated by recurrent episodes of pneu-
monia with atelectases, which were treated with bronchial la-
vage and antibiotics. An EMG showed a total absence of motor
and sensory responses in the peripheral nerves and phrenic
nerve. After 3 months some spontaneous diaphragmatic move-
ments returned and he was extubated. The respiration was still
not adequate, as indicated by carbon dioxide retention. To
counteract atelectasis he was treated for a further 6 months
with assisted ventilation at night and his respiratory function
slowly stabilized. A Witzel fistula was inserted and a tube was
placed in the jejunum and used for enteral feeding. All attempts
at gastric feeding were unsuccessful and led immediately to
gastric retention. The patient was maintained on small doses
of cyclosporin, prednisolone and azathioprine and no further
signs of rejection of the liver graft were seen.
The patient's neuromuscular status at present, two and a half
years after the transplantation, is about the same as before the
liver exchange. He has some function in his arms, although
motility and strength are reduced. His hands are held in volar
flexion with a decreased ability to make dorsal movements.
Contractures of the ankles and knees are present. The patient
can stand with support but is otherwise confined to his electric
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Fig. 2. Concentrations in urine of 5-aminolaevulinic acid, porphobilinogen, porphyrin and creatinine, before and after the liver
transplantation.
Arrow indicates the day of transplantation.
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curred, characterized by irritative modes, obstipation, general-
ized pains and respiratory distress. Two major exacerbations
took place in connection with a respiratory tract infection and
an operation for appendicitis, respectively. The patient is men-
tally normal and has started school at the regular time. He is
no longer in need for hospitalisation except during periods of
crises.
Biochemical Findings
Figures 2 — 5 show the porphyrin and porphyrin pre-
cursor excretion in urine and faeces as well as the
values for erythrocyte porphyrin and erythrocyte por-
phobilinogen deaminase and aminolaevulinate dehy-
dratase activities, before and after the liver transplan-
tation. The persistence of porphyrin and porphyrin
precursor excretion in urine after the liver exchange
is a striking and unexpected finding. The concentra-
tions varied from day to day in virtually the same
way as before the operation. There is a tendency for
5-aminolaevulinate and porphobilinogen concentra-
tions to increase with time. This would not have been
expected if the urinary excretion in the immediate
postoperative period represented only the excretion
of previously accumulated material. It is noteworthy
that the seizures on the 25th postoperative day were
not preceded by any increase in the excretion of 5-
aminolaevulinate and indeed, during the next few days
they were followed by a steep falHn precursor excre-
tion. On the second and third postoperative days the
urinary porphyrin profiles showed a predominance of
5 — 8 carboxylated moieties which was probably due
to an impaired decarboxylation activity in the par-
enchyma of a not yet stabilized graft (fig. 3). From
the fourth day on, the excretion profiles did not differ
significantly from those found two days before the
operation. After the liver transplantation the amounts
of porphyrin excreted in faeces considerably de-
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Fig. 3. Urinary porphyrin excretion patterns 2 days before and varying numbers of days after the liver transplantation.
8, 7, 6, 5, 4: number of porphyrin carboxylate side groups
4 I: coproporphyrin I isomer
4 III: coproporphyrin III isomer
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Fig. 4. Faecal porphyrin excretion patterns on three occasions
before, and 6 days after the liver transplantation.
8, 7, 6, 5, 4, 3: number of carboxylate side-chains
4 I: coproporphyrin I-isomer




462 nmol/g to 7 nmol/g. The porphyrin pattern, how-
ever, was unchanged, with 80 per cent protoporphyrin
and a coproporphyrin III/I isomer ratio larger than
unity. In the early postoperative period the values for
the red blood cell quantities were presumably influ-
enced by the large volume of erythrocytes given to
the patient. Thus, due to transfusions of normal donor
blood, erythrocyte aminolaevulinate dehydratase ac-
tivity was normalised postoperatively. Assays per-
formed one year after the transplantation showed a
regression in activity to the preoperative level.
Biochemical investigation of the liver explant was not
performed.
Discussion
Experience of the clinical features of severe amino-
laevulinate dehydratase deficiency porphyria is lim-
ited. The symptoms, however, seem to agree with
those known to occur in the other forms of acute
porphyria, as well as those seen in tyrosinaemia. When
evaluating the outcome of therapeutic measures in
this condition, attention therefore should be focused
on symptoms such as pain, paralysis, mental disturb-
ance, seizures, respiratory distress, vomiting, ileus,
tachycardia, hypertension and hyponatraemia (11,
18). With the exception of seizures, all the symptoms
mentioned were part of the patient's preoperative
porphyric attacks. However, even when occurring in
6 11 13 18 Days 25
Time
11 13 15 18 Days 25
Fig. 5. Erythrocyte porphyrin concentration and erythrocyte
porphobilinogen deaminase and aminolaevulinate de-
hydratase activities before and after the liver transplan-
tation.
clusters, the symptoms are not specific for porphyria,
especially not in a postoperative clinical setting, and
the absence of porphyric symptoms cannot be viewed
as proof that correction of the metabolic defect has
taken place. On the other hand, if the symptoms are
found to coincide with the occurrence of a porphyr-
inogenic factor, they are more likely to be due to the
basic disease. During a porphyric or tyrosinaemic
crisis the 5-aminolaevulinate excretion is, as a rule,
higher than normal, even if there is no correlation
between the magnitude of the excretion and the se-
verity of the symptoms (18). At least in tyrosinaemia,
a neurogenic crisis is not invariably accompanied by
further increases in porphyrin precursor excretion.
Nevertheless, if a clinical manifestation of porphyria
is accompanied by an augmented excretion of 5-ami-
nolaevulinate, this supports the diagnosis of a por-
phyric attack.
On the 25th postoperative day, symptoms suggestive
of an attack of acute porphyria developed in our
patient. Coinciding with the appearance of pulmonary
infiltrates and a rising serum titre of Candida antigen,
Eur. J. Glin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 10
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and after a period of high blood concentrations of
the porphyrinogenic agent, cyclosporin (19, 20), the
patient suddenly developed repeated attacks of epi-
leptiform seizures and respiratory failure as well as
sinus tachycardia, diastolic hypertension and hypon-
atraemia. The respiratory distress, however, could be
explained by the pulmonary infection, in combination
with persistent phrenic paralysis, as observed preop-
eratively. Furthermore, seizures are not common in
porphyria and were not a part of the preoperative
porphyric symptomatology of the patient. On the
other hand, neurological complications are frequently
observed postoperatively in transplantation patients
and symptoms may persist for months (21 —26). Cy-
closporin is probably involved since approximately 10
per cent of patients receiving the drug develop seizures
(27). A number of additional factors may be of im-
portance e.g., fluid retention, hypertension, hypona-
traemia, hypomagnesaemia, hyperosmolarity, pro-
longed ranitidine medication, high doses of steroids
and graft dysfunction (28). The concentration of mag-
nesium in blood seems to be of critical significance
(23, 29, 30). As seen in figure 1, during the week
preceding the neurological crisis, on the 25th post-
operative day, toxic blood concentrations of cyclo-
sporin were recorded as well as concentrations of
serum magnesium two standard deviations below the
normal mean. In view of this and the facts that
diastolic and systolic hypertension were present al-
ready on the day before the onset of the seizures and
that the 5-aminolaevulinate excretion did not increase
in connection with the attack, the overall clinical and
biochemical picture was interpreted as not being due
to induction of a latent porphyric condition, but as
secondary to cyclosporin neurotoxicity in combina-
tion with hypomagnesaemia and a chronically im-
paired pulmonary function, aggravated by pneu-
monia.
The second polyneuropathic crisis, which occurred
about 11 weeks after the transplantation, was less
acute in onset, but considerably more profound and
it persisted longer.
The onset and progress of the attacks were not ac-
companied by any significant changes in porphyrin
precursor excretion. Apart from the barbiturate and
benzodiazepine administration 5 weeks before and an
instance of bacteriuria 3 weeks prior to the crisis, no
factor known to trigger an attack of porphyria could
be identified. Values for serum cyclosporin and mag-
nesium concentrations are not available for the time
of deterioration, but in the preceding week borderline
and/or toxic values were repeatedly recorded for cy-
closporin, and serum magnesium concentrations were
somewhat low. It is known that liver transplant pa-
tients with cyclosporin-provoked neuropathy may de-
velop hemiplegia or tetraplegia (26, 28). In two cases
a spinal cord syndrome developed a considerable pe-
riod after an attack of seizures, as in our patient.
Although the generalized polyneuropathy in our pa-
tient was indistinguishable from similar episodes be-
fore the transplantation, the possibility cannot be
excluded that cyclosporin contributed to this neuro-
toxic attack. Unaltered porphyrin precursor excretion
gives some support for such a conclusion.
The postoperative clinical, pharmacological and bio-
chemical patterns were interactive and complex, and
it is very difficult to evaluate effects of the liver
transplant on the porphyric condition. After the two
early crises the patient has had a few further attacks.
However, he feels better than before, can spend his
time at home, and is no longer in need of total
parenteral nutrition. As a result of transfusions of
normal donor blood, erythrocyte aminolaevulinate
dehydratase activity normalised in the patient (fig. 5).
Assays performed 12 months after the operation
showed a regression of enzyme activity to the pre-
operative level. An effect of the liver exchange on the
erythroid aminolaevulinate dehydratase gene expres-
sion, was thus not observed.
The exchange of the aminolaevulinate dehydratase-
deficient liver for a normal organ did not affect the
high basal urinary excretion of porphyrins and por-
phyrin precursors, and these metabolites obviously
originate mainly from extrahepatic tissues that are
still affected by aminolaevulinate dehydratase defi-
ciency. The fact that the patient after the transplan-
tation is able to withstand severe porphyrinogenic
challenges, such as barbiturate medication, without
developing polyneuropathy, and without increasing
the 5-aminolaevulinate and porphobilinogen excre-
tion, indicates that the excess production of metabo-
lites takes place in cells that are not under the control
of the aminolaevulinate dehydratase-inductive mech-
anisms responsible for the activation of the disease
by such agents. The erythron is the major reservoir
for such cells in the body and it seems that a more
profound metabolic effect might be achieved by bone
marrow transplantation. Unfortunately, this ap-
proach is not possible because of the lack of a suitable
sibling donor.
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